Selective DPP4 inhibitors are marketed for the treatment of type 2 diabetes, and—as shown by us and others—this class of drugs can abrogate the truncation of CXCL10 by DPP4 in vitro and in vivo (22, 24). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.